Filing identity and reporting period
Important discrepancy: The supplied filing is Adtalem Global Education Inc.’s Form 10-Q, not a filing identified as Covista Inc. It covers the fiscal quarter and nine months ended March 31, 2024 (Adtalem’s fiscal 2024 third quarter), and was signed May 2, 2024. The requested “2023 Q3” period does not match the filing.
Adtalem operates Chamberlain University, Walden University, and medical and veterinary schools AUC, RUSM, and RUSVM. The financial statements present continuing operations unless noted.
Financial performance and liquidity
| Metric | Three months ended March 31, 2024 | Nine months ended March 31, 2024 |
|---|---|---|
| Revenue | $412.7 million, up 11.8% | $1,174.7 million, up 8.2% |
| Operating income | $61.7 million, up 3.9%; 15.0% margin versus 16.1% | $148.5 million, up 15.5%; 12.6% margin versus 11.8% |
| Net income | $36.8 million, down 19.7%; diluted EPS $0.93 versus $1.00 | $87.4 million, up 22.8%; diluted EPS $2.14 versus $1.54 |
| Adjusted net income (non-GAAP) | $59.4 million versus $51.6 million; adjusted diluted EPS $1.50 versus $1.13 | $149.0 million versus $146.9 million; adjusted diluted EPS $3.65 versus $3.19 |
For the quarter, revenue growth was offset in reported earnings by higher business integration, incentive compensation, bad-debt provision, and income tax expense, and by the prior-year gain on sale of assets and tax valuation allowance release. The nine-month comparison also reflects lower restructuring and intangible amortization costs, alongside an $18.5 million litigation reserve and other expense movements.
Segment revenue grew year over year in the quarter: Chamberlain 13.8%, Walden 13.3%, and Medical and Veterinary 6.1%. Enrollment increased 7.0% and 9.0% in Chamberlain’s January and March sessions, respectively, and was up 8.4% at Walden at March 31. Medical and Veterinary enrollment declined 4.5% for the January semester.
- Cash flow: Nine-month operating cash flow from continuing operations was $246.8 million, versus $149.8 million. Capital expenditures were $52.0 million, versus $19.1 million.
- Cash and liquidity: Cash and cash equivalents were $179.8 million at March 31, down from $273.7 million at June 30, 2023; cash, cash equivalents, and restricted cash totaled $187.3 million. Current assets were $387.6 million and current liabilities $509.1 million.
- Debt: Long-term debt carrying value was $648.1 million; principal totaled $658.3 million, comprising $405.0 million of 5.50% notes due 2028 and $253.3 million of Term Loan B due 2029. Term Loan B interest was 8.83% at quarter-end. The company prepaid $50.0 million of the term loan during the period and reported compliance with debt covenants.
- Available facility: The $400 million revolver had $242.1 million unused; $157.9 million was drawn under the facility for a letter of credit. Letters of credit in favor of the Department of Education totaled $241.9 million at March 31.
Material changes, outlook, and unusual items
- Adtalem repurchased 5.28 million shares for $252.6 million during the nine months. Treasury share repurchases were a major use of cash; the new $300 million authorization had $220.2 million remaining at March 31.
- Management expected fiscal 2024 capital spending of $65–$70 million, principally for IT, Chamberlain campus development, and medical and veterinary facility improvements. It expected additional Walden integration costs through the rest of fiscal 2024, at a decreasing rate. The filing does not provide specific full-year revenue or earnings guidance.
- Walden’s $28.5 million class-action settlement was accrued at March 31. The court preliminarily approved it on April 17, 2024; a fairness hearing was scheduled for July 23, 2024. If approved, Adtalem expected $5.5 million of indemnification from former owner Laureate. Walden also agreed to specified website disclosures, verifications, and program changes.
- ED’s fiscal 2022 composite score for Adtalem was 0.2; its institutions were allowed to continue participating in Title IV programs under provisional certifications, heightened cash monitoring, and reporting. ED subsequently allowed certain letter-of-credit reductions. Management said it did not expect these conditions to materially harm operations, but warned that loss or restriction of Title IV eligibility could have a material adverse effect.
- The Gainful Employment regulation is effective July 1, 2024. Adtalem said it was assessing potential effects on covered programs. The filing also discusses 90/10 compliance, accreditation and recertification matters, and borrower-defense applications; schools were responding to applications and believed none properly stated a claim.
- A short-seller report published January 30, 2024 adversely affected the share price, according to the filing. Adtalem warned that allegations could lead to shareholder suits or regulatory investigations.
- Other notable items include a $0.6 million write-down of a Naperville building classified as held for sale and ongoing costs from previously divested businesses. Management reported no interim goodwill or indefinite-lived intangible impairment trigger at March 31.
Key investor verification points
- Confirm the intended issuer and period: this source is Adtalem’s March 31, 2024 Form 10-Q, not a Covista Inc. 2023 Q3 filing.
- Track Title IV provisional status, ED letter-of-credit requirements, pending recertifications, and the potential effects of Gainful Employment and 90/10 rules.
- Verify final approval and payment terms for the $28.5 million Walden settlement, related program changes, and the expected Laureate indemnification.
- Assess whether enrollment growth—especially at Chamberlain and Walden—can sustain revenue growth while controlling bad debts, labor, marketing, and integration costs; monitor Medical and Veterinary enrollment.
- Review cash generation against substantial share repurchases, capital spending, debt service, and restricted liquidity, including the revolver availability and letter-of-credit obligations.
- Distinguish GAAP results from management’s non-GAAP adjusted measures and examine the quarter’s tax, integration, litigation, and prior-period asset-sale effects.